Goldman Sachs
TVRD

Goldman Sachs’s Tvardi Therapeutics TVRD Stock Holding History

Goldman Sachs’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,250
Closed -$616K – 6711
2017
Q3 		$616K Buy
1,250
+653
+109% +$327K ﹤0.01% 4954
2017
Q2 		$331K Buy
+597
New +$379K ﹤0.01% 5425

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Goldman Sachs's TVRD Position: Q1 2026 in Review

Goldman Sachs reduced its Tvardi Therapeutics (TVRD) stake by 28% in Q1 2026, selling an estimated $36.2K and leaving 23,898 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #6244.

Goldman Sachs first reported a position in TVRD in Q1 2016 and has held it in 37 quarters since. The position peaked at $9.62M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Goldman Sachs held 23,898 shares of Tvardi Therapeutics worth $76K as of Q1 2026.
  • Goldman Sachs sold 9,233 Tvardi Therapeutics shares in Q1 2026, an estimated $36.2K.
  • Tvardi Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6244 holding.
  • Goldman Sachs first reported a position in Tvardi Therapeutics in Q1 2016 and has held it in 37 quarters since.
  • Goldman Sachs's Tvardi Therapeutics position peaked at $9.62M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.